A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Radical Interoperability: Let’s break down the barriers on health care information systems

by Dr. Douglas Rosendale, DO, FACOS, FACS, DO, FACOS, FACS Federal Chief Medical Interoperability Officer, Deloitte Consulting LLP

Maybe it’s because I spent my early career as a “cowboy surgeon” in Colorado, but I’ve always been a bit of a maverick when it comes to using technology to improve health care delivery and outcomes. I was chief of surgery at the Veterans Administration when I founded and chaired the Health IT Innovation Development program under the White House Office of Science and Technology Policy to develop radical,

Read more

Disruptive potential of genomics could prompt life sciences companies to accelerate deal-making

by Susan Dettmar, principal, US M&A consultative services leader, and Kushan Biswas, Life Sciences M&A senior manager, Deloitte Consulting LLP

The ability to transform genomic information into effective diagnostics and therapies might represent the future of medicine. This potential is inspiring a new era of deal-making among biopharmaceutical and genomics companies that want to achieve a leadership position in next-generation therapies.

Within the next 12-18 months, 85 percent of global life sciences firms expect to leverage genomics data—either purchased data or through partnerships,

Read more

Virtual health: Extending the Military Health System’s outreach and reach-back

by Bruce Green, Managing Director, Chief Medical Officer, Deloitte Consulting LLP

As the functional manager of the US Air Force Medical Service and the 20th Air Force Surgeon General, I saw first-hand how digital technologies can extend the outreach and reach-back of the Military Health System (MHS) to improve operating efficiency and the patient experience. One technology which is already demonstrating its value, and which holds even greater promise for the future,

Read more

Could changes to funding streams put biomedical innovation at risk?

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

Funding and other support from private organizations and philanthropists has helped keep many medical researchers at the forefront of their fields, which has resulted in some cases in longer life expectancies and a higher quality of life for people affected by certain diseases. To help ensure science funding pipelines continue to be robust—and to help train the next generation of researchers—nonprofit biomedical funding organizations should pay close attention to the changing nature of giving.

Read more

Consumers want connected medical devices, but demand for digital experts could put further strains on the talent pool for medtech

by Pedro Arboleda, Managing Director, Deloitte Monitor

This week, my colleagues and I are attending AdvaMed’s annual MedTech Conference. Participants will hear about the latest innovations, such as new digital products that incorporate the latest advances in wireless technology and increasingly powerful computing capabilities for generating clinical and economic insights. But I worry the industry might overlook another important change that is occurring in parallel—the ability to attract the specific digital talent needed to deliver on the promise of connected medical devices.

Read more

Medtech companies can add value by uprooting low-value care

by Glenn Snyder, Principal, MedTech Practice Leader, Deloitte Consulting LLP

I’m headed to Philadelphia next week to moderate a panel of medtech CEOs at AdvaMed’s annual conference. Our topic: strategies to reduce low-value care. This is an important issue not just for medtech leaders, but for all health care stakeholders. The cost of low-value care is staggering. In the US alone, medical services that don’t necessarily benefit the patient top $200 billion annually.1

What is low-value care?

Read more